Private equity firm Qiming Venture Partners led a $106m Series D funding round in Asieris Pharmaceuticals, a developer of biotechnology products. Additional investors include YF Capital, CICC Capital, C&D, Gopher Asset Management, Hengxu Capital, IN Capital, V-Capital, Homsun Capital, IFSC, Triwise Capital, and Haoshuo Zhier Fund. “Apart from advancing competitive capacity, we are ready for drug commercialisation and manufacturing base construction. We also plan for new drugs listing toward soon-to-be done clinical trials or applications,” Kevin Pan, Asieris Founder and Chairman.